XOMA Royalty (XOMA) Gains from Sales and Divestitures (2012 - 2026)
XOMA Royalty's (XOMA) quarterly Gains from Sales and Divestitures came in at $23698.0 in Q1 2026, up 56.16% quarter-over-quarter from $15175.0 in Q4 2025.
XOMA Royalty (XOMA) Gains from Sales and Divestitures (2012 - 2026) Analysis & Trends
XOMA Royalty has disclosed Gains from Sales and Divestitures across 9 years of filings, most recently posting $23698.0 for Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $23698.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $23698.0 (changed N/A YoY), and the FY2025 annual result was $15175.0, changed N/A from the prior year.
- Gains from Sales and Divestitures came in at $23698.0 for Q1 2026 at XOMA Royalty, up from $15175.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $23698.0 in Q1 2026 to a low of $15175.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | XOMA Royalty | 5.48 Mn | -60.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23,698.00 |
| Mar 31, 2026 | 23,698.00 |
| Dec 31, 2025 | 15,175.00 |
| Dec 31, 2025 | 15,175.00 |
| Sep 30, 2025 | 15,175.00 |
| Sep 30, 2025 | 15,175.00 |
| Jun 30, 2025 | 15,175.00 |
| Jun 30, 2025 | 15,175.00 |
| Dec 31, 2018 | 18,047.00 |
| Dec 31, 2018 | 18,047.00 |
| Sep 30, 2018 | 17,614.00 |
| Sep 30, 2018 | 17,614.00 |
| Jun 30, 2018 | 17,614.00 |
| Jun 30, 2018 | 17,614.00 |
| Mar 31, 2018 | 13,360.00 |
| Mar 31, 2018 | 13,360.00 |
| Dec 31, 2017 | 62,405.00 |
| Dec 31, 2017 | 62,405.00 |
| Sep 30, 2017 | 60,886.00 |
| Sep 30, 2017 | 60,886.00 |